Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Despite continued protests at home and abroad, the FDA cleared silicon breast implants made by Sientra, making it the 3rd company with regulatory clearance to sell the controversial products in the U.S. The Santa Barbara, Calif.-based cosmetic device maker joins Johnson & Johnson (NYSE:JNJ) and Allergan (NYSE:AGN) in offering silicon-based breast implants to U.S. patients.
The National Venture Capital Assn. is spearheading a drive to get a bill through the U.S. Senate that would make it easier for small companies to raise money by going public. The "IPO On Ramp" measure would ease the regulatory requirements for IPOs and temporarily reduce the reporting burdens imposed by the Sarbanes-Oxley Act.
Zoll Medical (NSDQ:ZOLL) is winning a lot of Wall Street love this morning on the news of a $2.21 billion cash offer from Asahi Kasei Corp. (TYO:3407). ZOLL shares jumped 23.5% to $92.74 in morning trading today, after the Chelmsford, Mass.-based resuscitation device maker said it reached an agreement to merge with Asahi.